SEARCH

SEARCH BY CITATION

References

  • 1
    Levine JS, Branch DW, Rauch J. The antiphospholipid syndrome. N Engl J Med 2002; 346: 75263.
  • 2
    Galli M, Comfurius P, Maassen C, Hemker HC, de Baets MH, van Breda-Vriesman PJ, Barbui T, Zwaal RF, Bevers EM. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet 1990; 335: 15447.
  • 3
    McNeil HP, Simpson RJ, Chesterman CN, Krilis SA. Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: beta 2-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci USA 1990; 87: 41204.
  • 4
    Bouma B, de Groot PG, van den Elsen JM, Ravelli RB, Schouten A, Simmelink MJ, Derksen RH, Kroon J, Gros P. Adhesion mechanism of human beta(2)-glycoprotein I to phospholipids based on its crystal structure. EMBO J 1999; 18: 516674.
  • 5
    Schwarzenbacher R, Zeth K, Diederichs K, Gries A, Kostner GM, Laggner P, Prassl R. Crystal structure of human beta2-glycoprotein I: implications for phospholipid binding and the antiphospholipid syndrome. EMBO J 1999; 18: 622839.
  • 6
    Iverson GM, Victoria EJ, Marquis DM. Anti-beta2 glycoprotein I (beta2GPI) autoantibodies recognize an epitope on the first domain of beta2GPI. Proc Natl Acad Sci USA 1998; 95: 155426.
  • 7
    de Laat B, Derksen RH, Urbanus RT, de Groot PG. IgG antibodies that recognize epitope Gly40–Arg43 in domain I of beta 2-glycoprotein I cause LAC, and their presence correlates strongly with thrombosis. Blood 2005; 105: 15404.
  • 8
    Ioannou Y, Pericleous C, Giles I, Latchman DS, Isenberg DA, Rahman A. Binding of antiphospholipid antibodies to discontinuous epitopes on domain I of human beta(2)-glycoprotein I: mutation studies including residues R39 to R43. Arthritis Rheum 2007; 56: 28090.
  • 9
    Iverson GM, Reddel S, Victoria EJ, Cockerill KA, Wang YX, Marti-Renom MA, Sali A, Marquis DM, Krilis SA, Linnik MD. Use of single point mutations in domain I of beta 2-glycoprotein I to determine fine antigenic specificity of antiphospholipid autoantibodies. J Immunol 2002; 169: 7097103.
  • 10
    Ağar C, van Os GM, Morgelin M, Sprenger RR, Marquart JA, Urbanus RT, Derksen RH, Meijers JC, de Groot PG. Beta2-glycoprotein I can exist in 2 conformations: implications for our understanding of the antiphospholipid syndrome. Blood 2010; 116: 133643.
  • 11
    de Laat B, Derksen RH, van Lummel M, Pennings MT, de Groot PG. Pathogenic anti-beta2-glycoprotein I antibodies recognize domain I of beta2-glycoprotein I only after a conformational change. Blood 2006; 107: 191624.
  • 12
    Sène D, Piette JC, Cacoub P. Antiphospholipid antibodies, antiphospholipid syndrome and infections. Autoimmun Rev 2008; 7: 2727.
  • 13
    von Landenberg P, Lehmann HW, Knöll A, Dorsch S, Modrow S. Antiphospholipid antibodies in pediatric and adult patients with rheumatic disease are associated with parvovirus B19 infection. Arthritis Rheum 2003; 48: 193947.
  • 14
    Frauenknecht K, Lackner K, von Landenberg P. Antiphospholipid antibodies in pediatric patients with prolonged activated partial thromboplastin time during infection. Immunobiology 2005; 210: 799805.
  • 15
    Brito P, Penas S, Carneiro A, Palmares J, Reis FF. Spectral-domain optical coherence tomography features of acute syphilitic posterior placoid chorioretinitis: the role of autoimmune response in pathogenesis. Case Report Ophthalmol 2011; 1: 3944.
  • 16
    Galrão L, Brites C, Atta ML, Atta A, Lima I, Gonzalez F, Magalhães F, Santiago M. Antiphospholipid antibodies in HIV-positive patients. Clin Rheumatol 2007; 11: 182530.
  • 17
    Koutroubakis IE, Petinaki E, Anagnostopoulou E, Kritikos H, Mouzas IA, Kouroumalis EA, Manousos ON. Anti-cardiolipin and anti-β2-glycoprotein I antibodies in patients with inflammatory bowel disease. Dig Dis Sci 1998; 11: 250712.
  • 18
    Boin F, Franchini S, Colantuoni E, Rosen A, Wigley FM, Casciola-Rosen L. Independent association of anti-β2-glycoprotein I antibodies with macrovascular disease and mortality in scleroderma patients. Arthritis Rheum 2009; 60: 24809.
  • 19
    Santiago M, Martinelli R, Ko A, Reis EA, Fontes RD, Nascimento EG, Pierangeli S, Espinola R, Gharavi A. Anti-beta2 glycoprotein I and anticardiolipin antibodies in leptospirosis, syphilis and Kalaazar. Clin Exp Rheumatol 2001; 19: 42530.
  • 20
    Huh JY, Yi DY, Hwang SG, Choi JJ, Kang MS. Characterization of antiphospholipid antibodies in chronic hepatitis B infection. Korean J Hematol 2011; 46: 3640.
  • 21
    Sherer Y, Blank M, Shoenfeld Y. Antiphospholipid syndrome (APS): where does it come from? Best Pract Res Clin Rheumatol 2007; 21: 10718.
  • 22
    Blank M, Krause I, Fridkin Keller N, Kopolovic J, Goldberg I, Tobar A, Shoenfeld Y. Bacterial induction of autoantibodies to beta2-glycoprotein-I accounts for the infectious etiology of antiphospholipid syndrome. J Clin Invest 2002; 109: 797804.
  • 23
    Krause I, Blank M, Cervera R, Font J, Matthias T, Pfeiffer S, Wies I, Fraser A, Shoenfeld Y. Cross-reactive epitopes on beta2-glycoprotein-I and Saccharomyces cerevisiae in patients with the antiphospholipid syndrome. Ann N Y Acad Sci 2007; 1108: 4818.
  • 24
    Manco-Johnson MJ, Nuss R, Key N, Moertel C, Jacobson L, Meech S, Weinberg A, Lefkowitz J. Lupus anticoagulant and protein S deficiency in children with postvaricella purpura fulminans or thrombosis. J Pediatr 1996; 128: 31923.
  • 25
    American Academy of Pediatrics. Group A streptococcal infections. In: Pickering LK, Kimberlin DW, Lorber M, eds. Red Book: Report of Committee of Infectious Diseases, 26th edn. Elk Grove Village, IL: American Academy of Pediatrics, 2003: 61628.
  • 26
    Horbach DA, van Oort E, Donders RC, Derksen RH, de Groot PG. Lupus anticoagulant is the strongest risk factor for both venous and arterial thrombosis in patients with systemic lupus erythematosus. Comparison between different assays for the detection of antiphospholipid antibodies. Thromb Haemost 1996; 76: 91624.
  • 27
    Åkesson P, Schmidt KH, Cooney J, Björck L. M1 protein and protein H: IgGFc- and albumin-binding streptococcal surface proteins encoded by adjacent genes. Biochem J 1994; 300: 87786.
  • 28
    Åkesson P, Cooney J, Kishimoto F, Björck L. Protein H – a novel IgG binding bacterial protein. Mol Immunol 1990; 27: 52331.
  • 29
    Påhlman LI, Marx PF, Morgelin M, Lukomski S, Meijers JC, Herwald H. Thrombin-activatable fibrinolysis inhibitor binds to Streptococcus pyogenes by interacting with collagen-like proteins A and B. J Biol Chem 2007; 282: 2487381.
  • 30
    Urbanus RT, Siegerink B, Roest M, Rosendaal FR, de Groot PG, Algra A. Antiphospholipid antibodies and risk of myocardial infarction and ischaemic stroke in young women in the RATIO study: a case-control study. Lancet Neurol 2009; 8: 9981005.
  • 31
    Engel J, Furthmayr H. Electron microscopy and other physical methods for the characterization of extracellular matrix components: laminin, fibronectin, collagen IV, collagen VI, and proteoglycans. Methods Enzymol 1987; 145: 378.
  • 32
    Nilsson M, Wasylik S, Morgelin M, Olin AI, Meijers JC, Derksen RH, de Groot PG, Herwald H. The antibacterial activity of peptides derived from human beta-2 glycoprotein I is inhibited by protein H and M1 protein from Streptococcus pyogenes. Mol Microbiol 2008; 67: 48292.
  • 33
    de Laat B, Pengo V, Pabinger I, Musial J, Voskuyl AE, Bultink IE, Ruffatti A, Rozman B, Kveder T, de Moerloose P, Boehlen F, Rand J, Ulcova-Gallova Z, Mertens K, de Groot PG. The association between circulating antibodies against domain I of beta2-glycoprotein I and thrombosis: an international multicenter study. J Thromb Haemost 2009; 7: 176773.
  • 34
    Osterlund A, Popa R, Nikkila T, Scheynius A, Engstrand L. Intracellular reservoir of Streptococcus pyogenes in vivo: a possible explanation for recurrent pharyngotonsillitis. Laryngoscope 1997; 107: 6407.
  • 35
    Uthman IW, Gharavi AE. Viral infections and antiphospholipid antibodies. Semin Arthritis Rheum 2002; 31: 25663.
  • 36
    Asherson RA, Cervera R. Microvascular and microangiopathic antiphospholipid-associated syndromes (‘MAPS’): semantic or antisemantic? Autoimmun Rev 2008; 7: 1647.
  • 37
    Delbos V, Abgueguen P, Chennebault JM, Pichard E. Acute cytomegalovirus infection and venous thrombosis: role of antiphospholipid antibodies. J Infect 2007; 54: e4750.
  • 38
    Pengo V, Tripodi A, Reber G, Rand JH, Ortel TL, Galli M, de Groot PG. Update of the guidelines for lupus anticoagulant detection. Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost 2009; 7: 173740.
  • 39
    Blank M, Shoenfeld Y, Cabilly S, Heldman Y, Fridkin M, Katchalski-Katzir E. Prevention of experimental antiphospholipid syndrome and endothelial cell activation by synthetic peptides. Proc Natl Acad Sci USA 1999; 96: 51648.
  • 40
    Gharavi AE, Pierangeli SS, Espinola RG, Liu X, Colden-Stanfield M, Harris EN. Antiphospholipid antibodies induced in mice by immunization with a cytomegalovirus-derived peptide cause thrombosis and activation of endothelial cells in vivo. Arthritis Rheum 2002; 46: 54552.
  • 41
    Orts J, Colomina J, Zuniga A, Guerrero A. Cytomegalovirus infection and antiphospholipid syndrome in humans. Arthritis Rheum 2003; 48: 32967.
  • 42
    Pozzi N, Banzato A, Bettin S, Bison E, Pengo V, De Fillippis V. Chemical synthesis and characterization of wild-type and biotinylated N-terminal domain 1–64 of beta2-glycoprotein I. Protein Sci 2010; 19: 106578.
  • 43
    Rose NR. Molecular Autoimmunity. San Diego, CA: Academic Press, 1991.
  • 44
    Maas C, Hermeling S, Bouma B, Jiskoot W, Gebbink MF. A role for protein misfolding in immunogenicity of biopharmaceuticals. J Biol Chem 2007; 282: 222936.
  • 45
    Agar C, de Groot PG, Mörgelin M, Monk SD, van Os GM, Levels JH, de Laat B, Urbanus RT, Herwald H, van der Poll T, Meijers JC. {beta}2-glycoprotein I: a novel component of innate immunity. Blood 2011; 117: 693947.
  • 46
    Gotoh M, Matsuda J. Induction of anticardiolipin antibody and/or lupus anticoagulant in rabbits by immunization with lipoteichoic acid, lipopolysaccharide and lipid A. Lupus 1996; 6: 5937.
  • 47
    Dombroski D, Balasubramanian K, Schroit AJ. Phosphatidylserine expression on cell surfaces promotes antibody-dependent aggregation and thrombosis in beta2-glycoprotein I-immune mice. J Autoimmun 2000; 14: 2219.
  • 48
    Balasubramanian K, Schroit AJ. Characterization of phosphatidylserine-dependent b2-glycoprotein I macrophage interactions. J Biol Chem 1998; 273: 292727.
  • 49
    Gallistl S, Muntean W, Leschnik B, Meyers W. Longer aPTT values in healthy children than in adults: no single cause. Thromb Res 1997; 88: 3559.
  • 50
    Galli M, Barbui T. Antiphospholipid syndrome: clinical and diagnostic utility of laboratory tests. Semin Thromb Hemost 2005; 31: 1724.
  • 51
    Greinacher A. Opposites attract. Blood 2010; 115: 4401.